KORU Medical Systems, Inc. (KRMD) – What Are Analysts Saying About This Stock?

Shares of KORU Medical Systems, Inc. (NASDAQ:KRMD) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $7.00.

Several research analysts recently issued reports on the company. Wall Street Zen lowered KORU Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Research lowered KORU Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 30th. Craig Hallum reissued a “buy” rating and issued a $6.00 price target on shares of KORU Medical Systems in a research note on Thursday, August 6th. Finally, Weiss Ratings downgraded KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 29th.

Insiders Place Their Bets

In related news, insider Adam Kalbermatten bought 32,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were acquired at an average cost of $3.16 per share, with a total value of $101,120.00. Following the completion of the purchase, the insider directly owned 394,017 shares in the company, valued at $1,245,093.72. The trade was a 8.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 18.50% of the company’s stock.

Hedge Funds Weigh In On KORU Medical Systems

A number of hedge funds have recently bought and sold shares of the company. Algert Global LLC boosted its stake in KORU Medical Systems by 57.2% in the second quarter. Algert Global LLC now owns 22,737 shares of the company’s stock valued at $95,000 after acquiring an additional 8,270 shares during the last quarter. Bank of America Corp DE grew its holdings in KORU Medical Systems by 36.0% during the 1st quarter. Bank of America Corp DE now owns 37,971 shares of the company’s stock valued at $164,000 after buying an additional 10,045 shares in the last quarter. Vivaldi Capital Management LP increased its holdings in KORU Medical Systems by 51.6% during the 1st quarter. Vivaldi Capital Management LP now owns 29,885 shares of the company’s stock worth $129,000 after acquiring an additional 10,172 shares during the period. Sei Investments Co. boosted its stake in KORU Medical Systems by 14.8% during the first quarter. Sei Investments Co. now owns 93,772 shares of the company’s stock valued at $405,000 after buying an additional 12,062 shares during the period. Finally, Bard Associates Inc. purchased a new position in shares of KORU Medical Systems during the second quarter worth about $61,000. 58.60% of the stock is owned by hedge funds and other institutional investors.

KORU Medical Systems Trading Up 2.0%

NASDAQ:KRMD traded up $0.06 during mid-day trading on Friday, hitting $3.09. 105,444 shares of the company’s stock were exchanged, compared to its average volume of 167,885. KORU Medical Systems has a fifty-two week low of $2.86 and a fifty-two week high of $6.61. The firm has a market capitalization of $141.92 million, a P/E ratio of -77.25 and a beta of 0.47. The company has a 50 day simple moving average of $3.12 and a 200-day simple moving average of $3.97.

KORU Medical Systems (NASDAQ:KRMD) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.03. The firm had revenue of $12.05 million during the quarter, compared to analysts’ expectations of $11.62 million. KORU Medical Systems had a negative net margin of 4.03% and a negative return on equity of 10.63%. As a group, analysts expect that KORU Medical Systems will post -0.02 earnings per share for the current year.

About KORU Medical Systems

KORU Medical Systems, Inc develops, manufactures and markets portable infusion systems and related accessories for the home and alternate-site infusion markets. The company’s products are designed to support the controlled delivery of specialty drugs, including subcutaneous immunoglobulin (SCIG) therapies, through ambulatory infusion systems.

KORU’s principal product platform is the Freedom Syringe Infusion System, which includes ambulatory syringe pumps such as the Freedom60, FreedomEdge and FreedomIQ, along with flow-control tubing sets and other disposable components.